{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:14:05Z","timestamp":1791328445004,"version":"4.3.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The objective of this study was to evaluate the quality of anticoagulation by the time in therapeutic range (TTR) for patients with 12-week INR follow-up interval.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>From January 2018 to December 2020, a selective group of patients who underwent mechanical valve replacement and followed up at our anticoagulation clinic for adjustment of warfarin dose were enrolled. The incidences of complications of anticoagulation therapy were reported by linearized rates. TTR was calculated by the Rosendaal linear interpolation method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two hundred and seventy-four patients were eligible for this study. The mean age of these patients was 52.8 \u00b1 12.7 years, and 65.7% (180 cases) of them were females. The mean duration of warfarin therapy was 16.7 \u00b1 28.1 months. A total of 1309 INR values were collected, representing 66789 patient days. In this study, the mean TTR was 63.7% \u00b1 18.6%, weekly doses of warfarin were 20.6 \u00b1 6.0 mg\/weekly, and the mean monitoring interval for the patient was 53.6 \u00b1 27.1 days. There were 153 cases in good TTR group (TTR \u2265 60%) and 121 cases in poor TTR group (TTR &amp;lt; 60%). The calculated mean TTR in both groups was 42.6% \u00b1 22.1% and 74.8% \u00b1 10.4%, respectively. Compared with the TTR \u2265 60% group, the TTR &amp;lt; 60% group exhibited a more prevalence of female gender (<jats:italic>p<\/jats:italic> = 0.001), atrial fibrillation (<jats:italic>p<\/jats:italic> &amp;lt; 0.001), NYHA \u2265 III (<jats:italic>p<\/jats:italic> &amp;lt; 0.001), and lower preoperative left ventricular ejection fraction (LVEF, <jats:italic>p<\/jats:italic> = <jats:italic>0.032<\/jats:italic>). In multivariate analysis, female gender (<jats:italic>p<\/jats:italic> = 0.023) and atrial fibrillation (<jats:italic>p<\/jats:italic> = 0.011) were associated with TTR &amp;lt; 60%. The incidence of major bleeding and thromboembolic events was 2.7% and 1.1% patient-years, respectively. There was one death which resulted from cerebral hemorrhage. The incidence of death was 0.5% patient-years. The difference in anticoagulation-related complications between the TTR &amp;lt; 60% group and the TTR \u2265 60% group was not statistically significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>For patients with stable international normalized ratio monitoring results who are follow-up at anticoagulation clinics, a 12-week monitoring interval has an acceptable quality of anticoagulation. The female gender and atrial fibrillation were associated with TTR &amp;lt; 60%.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.925571","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T05:48:15Z","timestamp":1662702495000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Rosendaal linear interpolation method appraising of time in therapeutic range in patients with 12-week follow-up interval after mechanical heart valve replacement"],"prefix":"10.3389","volume":"9","author":[{"given":"Xiliang","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xijun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/01.CIR.89.2.635","article-title":"Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses.","volume":"89","author":"Cannegieter","year":"1994","journal-title":"Circulation."},{"key":"B2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jjcc.2013.11.015","article-title":"Long-term PT-INR levels and the clinical events in the patients with non-valvular atrial fibrillation: A special reference to low-intensity warfarin therapy.","volume":"64","author":"Takarada","year":"2014","journal-title":"J Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.thromres.2014.06.007","article-title":"Thromboembolism, major bleeding and mortality in patients with mechanical heart valves- a population-based cohort study?.","volume":"134","author":"Labaf","year":"2014","journal-title":"Thromb Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1538-7836.2010.03756.x","article-title":"Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users.","volume":"8","author":"Witt","year":"2010","journal-title":"J Thromb Haemost."},{"key":"B5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s11239-013-0887-y","article-title":"Frequency of monitoring, non-adherence, and other topics dear to an anticoagulation clinic provider.","volume":"35","author":"Clark","year":"2013","journal-title":"J Thromb Thrombolysis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/1755-5922.12115","article-title":"Feasibility of extended-interval follow-up for patients receiving warfarin.","volume":"33","author":"Carris","year":"2015","journal-title":"Cardiovasc Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.7326\/0003-4819-155-10-201111150-00003","article-title":"Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: A randomized trial.","volume":"155","author":"Schulman","year":"2015","journal-title":"Ann Intern Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1538-7836.2008.03199.x","article-title":"Warfarin dose management affects INR control.","volume":"7","author":"Rose","year":"2009","journal-title":"J Thromb Haemost."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1111\/j.1538-7836.2008.03075.x","article-title":"Warfarin for atrial fibrillation in community-based practise.","volume":"6","author":"Rose","year":"2008","journal-title":"J Thromb Haemost."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000170","article-title":"Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic.","volume":"2","author":"Rodriguez","year":"2013","journal-title":"J Am Heart Assoc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s11239-013-0878-z","article-title":"Point-of-care patient self-monitoring of oral vitamin K antagonist therapy.","volume":"35","author":"Ansell","year":"2013","journal-title":"J Thromb Thrombolysis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: A systematic review.","volume":"1","author":"Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"B13","doi-asserted-by":"publisher","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines.","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v13.i9.483","article-title":"Patients\u2019time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic.","volume":"13","author":"Lee","year":"2021","journal-title":"World J Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1161\/CIRCULATIONAHA.113.003132","article-title":"Apixaban compared with warfarin for stroke prevention in atrial fibrillation.","volume":"127","author":"Gallego","year":"2013","journal-title":"Circulation."},{"key":"B16","doi-asserted-by":"publisher","first-page":"FC04","DOI":"10.7860\/JCDR\/2016\/21955.8457","article-title":"Evaluation of time in therapeutic range (TTR) in patients with non-valvular atrial fibrillation receiving treatment with warfarin in Tehran, Iran: A cross-sectional study.","volume":"10","author":"Farsad","year":"2016","journal-title":"J Clin Diagn Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1023\/B:THRO.0000011377.78585.63","article-title":"Quality assessment of anticoagulation dose management: Comparative evaluation of measures of time-in-therapeutic range.","volume":"15","author":"Schmitt","year":"2003","journal-title":"J Thromb Thrombolysis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/021849230501300410","article-title":"Low-dose anticoagulation in Chinese patients with mechanical heart valves.","volume":"13","author":"Zhou","year":"2005","journal-title":"Asian Cardiovasc Thorac Ann."},{"key":"B19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/BF02600026","article-title":"A computerized intervention to improve timing of outpatient follow-up: A multicenter randomized trial in patients treated with warfarin. National Consortium of Anticoagulation Clinics.","volume":"9","author":"Fihn","year":"1994","journal-title":"J Gen Intern Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","article-title":"Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.","volume":"118","author":"Connolly","year":"2008","journal-title":"Circulation."},{"key":"B21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejim.2013.12.013","article-title":"The quality of oral anticoagulation in general practice in patients with atrial fibrillation.","volume":"25","author":"Mueller","year":"2014","journal-title":"Eur J Intern Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11239-011-0555-z","article-title":"Practical issues with vitamin K antagonists: Elevated INRs, low time-in-therapeutic range, and warfarin failure.","volume":"31","author":"Lee","year":"2011","journal-title":"J Thromb Thrombolysis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1111\/j.1532-5415.2010.02967.x","article-title":"The quality of warfarin prescribing and monitoring in Veterans Affairs nursing homes.","volume":"58","author":"Aspinall","year":"2010","journal-title":"J Am Geriatr Soc."},{"key":"B24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.thromres.2008.09.016","article-title":"Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control.","volume":"124","author":"Morgan","year":"2009","journal-title":"Thromb Res."},{"key":"B25","first-page":"102","article-title":"Quality of anticoagulation with warfarin across Kuwait.","volume":"54","author":"Zubaid","year":"2013","journal-title":"Hellenic J Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3988\/jcn.2017.13.3.273","article-title":"Quality of anticoagulation with warfarin in Korean patients with atrial fibrillation and prior stroke: A multicenter retrospective observational study.","volume":"13","author":"Hong","year":"2017","journal-title":"J Clin Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.thromres.2021.04.011","article-title":"Time in therapeutic range is lower in women than in men and is not explained by differences in age or comorbidity.","volume":"203","author":"Avarello","year":"2021","journal-title":"Thrombosis Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/phar.2324","article-title":"Predictors of warfarin time in therapeutic range after continuous-flow left ventricular assist device.","volume":"39","author":"Henderson","year":"2019","journal-title":"Pharmacother J Hum Pharmacol Drug Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: The SAMe-TTR score.","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest."},{"key":"B30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/1062860607303003","article-title":"Quality of clinical documentation and anticoagulation control in patients with chronic nonvalvular atrial fibrillation in routine medical care.","volume":"22","author":"Ansell","year":"2007","journal-title":"Am J Med Qual."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0149-2918(03)80167-4","article-title":"Factors influencing physicians\u2019 reported use of anticoagulation therapy in nonvalvular atrial fibrillation: A cross-sectional survey.","volume":"25","author":"Gross","year":"2003","journal-title":"Clin Ther."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.925571\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T05:48:18Z","timestamp":1662702498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.925571\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":31,"alternative-id":["10.3389\/fcvm.2022.925571"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.925571","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,9]]},"article-number":"925571"}}